Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C29H40N6O6S |
| Molecular Weight | 600.73 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CSCC[C@H](N(C)C(=O)[C@H](CC1=CC=CC=C1)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC2=CC=C(O)C=C2)C(N)=O
InChI
InChIKey=FWDIKROEWJOQIQ-JMBSJVKXSA-N
InChI=1S/C29H40N6O6S/c1-18(33-28(40)22(30)15-20-9-11-21(36)12-10-20)27(39)32-17-25(37)34-23(16-19-7-5-4-6-8-19)29(41)35(2)24(26(31)38)13-14-42-3/h4-12,18,22-24,36H,13-17,30H2,1-3H3,(H2,31,38)(H,32,39)(H,33,40)(H,34,37)/t18-,22+,23+,24+/m1/s1
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cardiovascular properties of metkephamid, a delta opioid receptor agonist, in man. | 1985-02 |
|
| Metkephamid (Tyr-D-ala-Gly-Phe-N(Me)Met-NH2), a potent opioid peptide: receptor binding and analgesic properties. | 1982-09-01 |
|
| Metkephamid, a systemically active analog of methionine enkephalin with potent opioid alpha-receptor activity. | 1981-02-06 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6872419
The efficacy, safety, and time course of analgesia with 70 or 140 mg metkephamid were compared with those of 100 mg meperidine and placebo in 59 hospitalized women with severe postpartum episiotomy pain.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MNL20FXH9Y
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
100000080918
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
DTXSID30985694
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
CHEMBL2220405
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
5464184
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
Metkephamid
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
SUB08899MIG
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
66960-34-7
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
C028208
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
C174718
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY | |||
|
4859
Created by
admin on Mon Mar 31 19:21:47 GMT 2025 , Edited by admin on Mon Mar 31 19:21:47 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)